FULC
USDFulcrum Therapeutics Inc. Common Stock
Цена в режиме реального времени
График цен
Ключевые показатели
Рыночные показатели
Открытие
$8.830
Максимум
$9.020
Минимум
$8.300
Объем
0.37M
Фундаментальные показатели компании
Рыночная капитализация
453.0M
Отрасль
Биотехнология
Страна
United States
Статистические данные торговли
Средний объем
0.53M
Биржа
NGM
Валюта
USD
52-недельный диапазон
Связанные новости
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
― Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ― ― Live and Webcast Investor Event with Fulcrum Leadership and Medical Experts will be
RBC Capital Maintains Sector Perform on Fulcrum Therapeutics, Raises Price Target to $7
RBC Capital analyst Luca Issi maintains Fulcrum Therapeutics with a Sector Perform and raises the price target from $5 to $7.
Piper Sandler Reiterates Overweight on Fulcrum Therapeutics, Raises Price Target to $16
Piper Sandler analyst Edward Tenthoff reiterates Fulcrum Therapeutics with a Overweight and raises the price target from $12.5 to $16.
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
― Announced encouraging results in July 2025 from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Enrollment complete in the 20 mg dose cohort (n=12) of the
Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET
CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives
Связанные акции
DNLI
Denali Therapeutics Inc.
AVAH
Aveanna Healthcare Holdings Inc.
CURI
CuriosityStream Inc.
MACAW
Moringa Acquisition Corp Warrant
ATLCP
Atlanticus Holdings Corporation 7.625% Series B Cumulative Perpetual Preferred Stock no par value per share
Оставаться в курсе
Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.